Dosage of Capecitabine and Cyclophosphamide Combination Therapy in Patients with Metastatic Breast Cancer
Background: Capecitabine is a highly effective and well-tolerated treatment for metastatic breast cancer (MBC) and extends survival when combined with docetaxel. Capecitabine and cyclophosphamide are orally administered and have preclinical synergy and non-overlapping toxicities. Patients and Method...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2007-03, Vol.27 (2), p.1009-1013 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1013 |
|---|---|
| container_issue | 2 |
| container_start_page | 1009 |
| container_title | Anticancer research |
| container_volume | 27 |
| creator | OHNO, Shinji MITSUYAMA, Shoshu TAMURA, Kazuo NISHIMURA, Reiki TANAKA, Maki HAMADA, Yuzo KUROKI, Shoji |
| description | Background: Capecitabine is a highly effective and well-tolerated treatment for metastatic breast cancer (MBC) and extends
survival when combined with docetaxel. Capecitabine and cyclophosphamide are orally administered and have preclinical synergy
and non-overlapping toxicities. Patients and Methods: Sixteen pretreated MBC patients received escalating doses of oral capecitabine
628 to 829 mg/m 2 twice daily (bid) plus oral cyclophosphamide 33 to 50 mg/m 2 bid, on days 1 to 14 every 21 days. Results: Among the ten patients receiving capecitabine/cyclophosphamide 829/33 mg/m 2 bid on days 1 to 14, two experienced dose-limiting toxicities (DLT, treatment delay >1 week due to grade 2 leukopenia). Because
neither patient developed further grade >1 toxicity and none of the patients experienced grade 3/4 toxicities or further DLTs,
this dose level is the recommended regimen, producing partial responses in two of five evaluable patients. Conclusion: The
recommended all oral capecitabine/cyclophosphamide combination regimen is well tolerated and active in MBC, and is being evaluated
in a phase II study in anthracycline-pretreated MBC. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_19626533</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19626533</sourcerecordid><originalsourceid>FETCH-LOGICAL-h300t-5b342fa9b0a0605aef50800a70ccbbe00daf40aeeec216d06b7bb0feae15a5483</originalsourceid><addsrcrecordid>eNpFkE1LxDAQhoso7rr6FyQXvRWmTZO0R62fsKKH9Vwm6XQb6ZdJF9l_b8CVPc3wvg8PzJxEy0QVSawEh9NoCamAWAGIRXTh_ReAlEXOz6NFojIpUi6WkX0YPW6JjQ0rcSJjZ9R2IIZDzcq96capHf3UYm9rYuXYhxJnOw5s05LDac_swD5CQsPs2Y-dW_ZGM_o5RIbdOwprEA-G3GV01mDn6eowV9Hn0-OmfInX78-v5d06bjnAHAvNs7TBQgOCBIHUCMgBUIExWhNAjU0GSEQmTWQNUiutoSGkRKDIcr6Kbv-8kxu_d-TnqrfeUNfhQOPOV0khUyk4D-D1AdzpnupqcrZHt6_-nxOAmwOA3mDXuHCH9Ucul0LJFI5ca7ftj3VU-R67Lmh5hS5VVVolAAX_BRMrfNg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19626533</pqid></control><display><type>article</type><title>Dosage of Capecitabine and Cyclophosphamide Combination Therapy in Patients with Metastatic Breast Cancer</title><source>MEDLINE</source><source>Free E-Journal (出版社公開部分のみ）</source><creator>OHNO, Shinji ; MITSUYAMA, Shoshu ; TAMURA, Kazuo ; NISHIMURA, Reiki ; TANAKA, Maki ; HAMADA, Yuzo ; KUROKI, Shoji</creator><creatorcontrib>OHNO, Shinji ; MITSUYAMA, Shoshu ; TAMURA, Kazuo ; NISHIMURA, Reiki ; TANAKA, Maki ; HAMADA, Yuzo ; KUROKI, Shoji ; Kyushu Breast Cancer Study Group</creatorcontrib><description>Background: Capecitabine is a highly effective and well-tolerated treatment for metastatic breast cancer (MBC) and extends
survival when combined with docetaxel. Capecitabine and cyclophosphamide are orally administered and have preclinical synergy
and non-overlapping toxicities. Patients and Methods: Sixteen pretreated MBC patients received escalating doses of oral capecitabine
628 to 829 mg/m 2 twice daily (bid) plus oral cyclophosphamide 33 to 50 mg/m 2 bid, on days 1 to 14 every 21 days. Results: Among the ten patients receiving capecitabine/cyclophosphamide 829/33 mg/m 2 bid on days 1 to 14, two experienced dose-limiting toxicities (DLT, treatment delay >1 week due to grade 2 leukopenia). Because
neither patient developed further grade >1 toxicity and none of the patients experienced grade 3/4 toxicities or further DLTs,
this dose level is the recommended regimen, producing partial responses in two of five evaluable patients. Conclusion: The
recommended all oral capecitabine/cyclophosphamide combination regimen is well tolerated and active in MBC, and is being evaluated
in a phase II study in anthracycline-pretreated MBC.</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 17465235</identifier><language>eng</language><publisher>Attiki: International Institute of Anticancer Research</publisher><subject><![CDATA[Administration, Oral ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Biological and medical sciences ; Breast Neoplasms - drug therapy ; Breast Neoplasms - pathology ; Capecitabine ; Cyclophosphamide - administration & dosage ; Cyclophosphamide - adverse effects ; Deoxycytidine - administration & dosage ; Deoxycytidine - adverse effects ; Deoxycytidine - analogs & derivatives ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Synergism ; Fluorouracil - administration & dosage ; Fluorouracil - adverse effects ; Fluorouracil - analogs & derivatives ; Gynecology. Andrology. Obstetrics ; Humans ; Mammary gland diseases ; Medical sciences ; Middle Aged ; Neoplasm Metastasis ; Tumors]]></subject><ispartof>Anticancer research, 2007-03, Vol.27 (2), p.1009-1013</ispartof><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18657620$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17465235$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>OHNO, Shinji</creatorcontrib><creatorcontrib>MITSUYAMA, Shoshu</creatorcontrib><creatorcontrib>TAMURA, Kazuo</creatorcontrib><creatorcontrib>NISHIMURA, Reiki</creatorcontrib><creatorcontrib>TANAKA, Maki</creatorcontrib><creatorcontrib>HAMADA, Yuzo</creatorcontrib><creatorcontrib>KUROKI, Shoji</creatorcontrib><creatorcontrib>Kyushu Breast Cancer Study Group</creatorcontrib><title>Dosage of Capecitabine and Cyclophosphamide Combination Therapy in Patients with Metastatic Breast Cancer</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>Background: Capecitabine is a highly effective and well-tolerated treatment for metastatic breast cancer (MBC) and extends
survival when combined with docetaxel. Capecitabine and cyclophosphamide are orally administered and have preclinical synergy
and non-overlapping toxicities. Patients and Methods: Sixteen pretreated MBC patients received escalating doses of oral capecitabine
628 to 829 mg/m 2 twice daily (bid) plus oral cyclophosphamide 33 to 50 mg/m 2 bid, on days 1 to 14 every 21 days. Results: Among the ten patients receiving capecitabine/cyclophosphamide 829/33 mg/m 2 bid on days 1 to 14, two experienced dose-limiting toxicities (DLT, treatment delay >1 week due to grade 2 leukopenia). Because
neither patient developed further grade >1 toxicity and none of the patients experienced grade 3/4 toxicities or further DLTs,
this dose level is the recommended regimen, producing partial responses in two of five evaluable patients. Conclusion: The
recommended all oral capecitabine/cyclophosphamide combination regimen is well tolerated and active in MBC, and is being evaluated
in a phase II study in anthracycline-pretreated MBC.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - pathology</subject><subject>Capecitabine</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Cyclophosphamide - adverse effects</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - adverse effects</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Drug Synergism</subject><subject>Fluorouracil - administration & dosage</subject><subject>Fluorouracil - adverse effects</subject><subject>Fluorouracil - analogs & derivatives</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Tumors</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1LxDAQhoso7rr6FyQXvRWmTZO0R62fsKKH9Vwm6XQb6ZdJF9l_b8CVPc3wvg8PzJxEy0QVSawEh9NoCamAWAGIRXTh_ReAlEXOz6NFojIpUi6WkX0YPW6JjQ0rcSJjZ9R2IIZDzcq96capHf3UYm9rYuXYhxJnOw5s05LDac_swD5CQsPs2Y-dW_ZGM_o5RIbdOwprEA-G3GV01mDn6eowV9Hn0-OmfInX78-v5d06bjnAHAvNs7TBQgOCBIHUCMgBUIExWhNAjU0GSEQmTWQNUiutoSGkRKDIcr6Kbv-8kxu_d-TnqrfeUNfhQOPOV0khUyk4D-D1AdzpnupqcrZHt6_-nxOAmwOA3mDXuHCH9Ucul0LJFI5ca7ftj3VU-R67Lmh5hS5VVVolAAX_BRMrfNg</recordid><startdate>20070301</startdate><enddate>20070301</enddate><creator>OHNO, Shinji</creator><creator>MITSUYAMA, Shoshu</creator><creator>TAMURA, Kazuo</creator><creator>NISHIMURA, Reiki</creator><creator>TANAKA, Maki</creator><creator>HAMADA, Yuzo</creator><creator>KUROKI, Shoji</creator><general>International Institute of Anticancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7TO</scope><scope>H94</scope></search><sort><creationdate>20070301</creationdate><title>Dosage of Capecitabine and Cyclophosphamide Combination Therapy in Patients with Metastatic Breast Cancer</title><author>OHNO, Shinji ; MITSUYAMA, Shoshu ; TAMURA, Kazuo ; NISHIMURA, Reiki ; TANAKA, Maki ; HAMADA, Yuzo ; KUROKI, Shoji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h300t-5b342fa9b0a0605aef50800a70ccbbe00daf40aeeec216d06b7bb0feae15a5483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - pathology</topic><topic>Capecitabine</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Cyclophosphamide - adverse effects</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - adverse effects</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Drug Synergism</topic><topic>Fluorouracil - administration & dosage</topic><topic>Fluorouracil - adverse effects</topic><topic>Fluorouracil - analogs & derivatives</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>OHNO, Shinji</creatorcontrib><creatorcontrib>MITSUYAMA, Shoshu</creatorcontrib><creatorcontrib>TAMURA, Kazuo</creatorcontrib><creatorcontrib>NISHIMURA, Reiki</creatorcontrib><creatorcontrib>TANAKA, Maki</creatorcontrib><creatorcontrib>HAMADA, Yuzo</creatorcontrib><creatorcontrib>KUROKI, Shoji</creatorcontrib><creatorcontrib>Kyushu Breast Cancer Study Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>OHNO, Shinji</au><au>MITSUYAMA, Shoshu</au><au>TAMURA, Kazuo</au><au>NISHIMURA, Reiki</au><au>TANAKA, Maki</au><au>HAMADA, Yuzo</au><au>KUROKI, Shoji</au><aucorp>Kyushu Breast Cancer Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dosage of Capecitabine and Cyclophosphamide Combination Therapy in Patients with Metastatic Breast Cancer</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2007-03-01</date><risdate>2007</risdate><volume>27</volume><issue>2</issue><spage>1009</spage><epage>1013</epage><pages>1009-1013</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>Background: Capecitabine is a highly effective and well-tolerated treatment for metastatic breast cancer (MBC) and extends
survival when combined with docetaxel. Capecitabine and cyclophosphamide are orally administered and have preclinical synergy
and non-overlapping toxicities. Patients and Methods: Sixteen pretreated MBC patients received escalating doses of oral capecitabine
628 to 829 mg/m 2 twice daily (bid) plus oral cyclophosphamide 33 to 50 mg/m 2 bid, on days 1 to 14 every 21 days. Results: Among the ten patients receiving capecitabine/cyclophosphamide 829/33 mg/m 2 bid on days 1 to 14, two experienced dose-limiting toxicities (DLT, treatment delay >1 week due to grade 2 leukopenia). Because
neither patient developed further grade >1 toxicity and none of the patients experienced grade 3/4 toxicities or further DLTs,
this dose level is the recommended regimen, producing partial responses in two of five evaluable patients. Conclusion: The
recommended all oral capecitabine/cyclophosphamide combination regimen is well tolerated and active in MBC, and is being evaluated
in a phase II study in anthracycline-pretreated MBC.</abstract><cop>Attiki</cop><pub>International Institute of Anticancer Research</pub><pmid>17465235</pmid><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-7005 |
| ispartof | Anticancer research, 2007-03, Vol.27 (2), p.1009-1013 |
| issn | 0250-7005 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_19626533 |
| source | MEDLINE; Free E-Journal (出版社公開部分のみ） |
| subjects | Administration, Oral Adult Aged Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Biological and medical sciences Breast Neoplasms - drug therapy Breast Neoplasms - pathology Capecitabine Cyclophosphamide - administration & dosage Cyclophosphamide - adverse effects Deoxycytidine - administration & dosage Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Dose-Response Relationship, Drug Drug Administration Schedule Drug Synergism Fluorouracil - administration & dosage Fluorouracil - adverse effects Fluorouracil - analogs & derivatives Gynecology. Andrology. Obstetrics Humans Mammary gland diseases Medical sciences Middle Aged Neoplasm Metastasis Tumors |
| title | Dosage of Capecitabine and Cyclophosphamide Combination Therapy in Patients with Metastatic Breast Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T07%3A32%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dosage%20of%20Capecitabine%20and%20Cyclophosphamide%20Combination%20Therapy%20in%20Patients%20with%20Metastatic%20Breast%20Cancer&rft.jtitle=Anticancer%20research&rft.au=OHNO,%20Shinji&rft.aucorp=Kyushu%20Breast%20Cancer%20Study%20Group&rft.date=2007-03-01&rft.volume=27&rft.issue=2&rft.spage=1009&rft.epage=1013&rft.pages=1009-1013&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E19626533%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19626533&rft_id=info:pmid/17465235&rfr_iscdi=true |